Terms: = Endocrine gland cancer AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras AND Prognosis
139 results:
1. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
[TBL] [Abstract] [Full Text] [Related]
2. Synergistic effect of antagonists to KRas4B/PDE6 molecular complex in pancreatic cancer.
Briseño-Díaz P; Schnoor M; Bello-Ramirez M; Correa-Basurto J; Rojo-Domínguez A; Arregui L; Vega L; Núñez-González E; Palau-Hernández LA; Parra-Torres CG; García Córdova OM; Zepeda-Castilla E; Torices-Escalante E; Domínguez-Camacho L; Xoconostle-Cazares B; Meraz-Ríos MA; Delfín-Azuara S; Carrión-Estrada DA; Villegas-Sepúlveda N; Hernández-Rivas R; Thompson-Bonilla MDR; Vargas M
Life Sci Alliance; 2023 Dec; 6(12):. PubMed ID: 37813486
[TBL] [Abstract] [Full Text] [Related]
3.
Alamri AM; Alkhilaiwi FA; Khan NU; Tasleem M
Anticancer Agents Med Chem; 2023; 23(19):2111-2126. PubMed ID: 37287303
[TBL] [Abstract] [Full Text] [Related]
4. Tumor-Infiltrating Immune Cell Landscapes in the Lymph Node Metastasis of Papillary Thyroid cancer.
Amanullah M; Pan M; Lu K; Pan X; Lu Y; Luo D; Liu P
Curr Oncol; 2023 Feb; 30(3):2625-2641. PubMed ID: 36975413
[TBL] [Abstract] [Full Text] [Related]
5. A comprehensive review of pancreatic cancer and its therapeutic challenges.
Jiang S; Fagman JB; Ma Y; Liu J; Vihav C; Engstrom C; Liu B; Chen C
Aging (Albany NY); 2022 Sep; 14(18):7635-7649. PubMed ID: 36173644
[TBL] [Abstract] [Full Text] [Related]
6. Bcl-2 and Noxa are potential prognostic indicators for patients with gastroenteropancreatic neuroendocrine neoplasms.
Guo Y; Zhang L; Zhang N; Chen L; Luo Q; Liu M; Yang D; Chen J
Endocrine; 2022 Oct; 78(1):159-168. PubMed ID: 35895181
[TBL] [Abstract] [Full Text] [Related]
7. Clinicopathological and Molecular Features of Secondary cancer (Metastasis) to the Thyroid and Advances in Management.
Nguyen M; He G; Lam AK
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328664
[TBL] [Abstract] [Full Text] [Related]
8. Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer.
Semsar-Kazerooni K; Morand GB; Payne AE; da Silva SD; Forest VI; Hier MP; Pusztaszeri MP; Tamilia M; Payne RJ
J Otolaryngol Head Neck Surg; 2022 Mar; 51(1):9. PubMed ID: 35246262
[TBL] [Abstract] [Full Text] [Related]
9. Recent Advances in Pancreatic cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature.
Schlick K; Kiem D; Greil R
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680101
[TBL] [Abstract] [Full Text] [Related]
10. Whole-genome Sequencing of Follicular Thyroid Carcinomas Reveal Recurrent Mutations in MicroRNA Processing Subunit DGCR8.
Paulsson JO; Rafati N; DiLorenzo S; Chen Y; Haglund F; Zedenius J; Juhlin CC
J Clin Endocrinol Metab; 2021 Oct; 106(11):3265-3282. PubMed ID: 34171097
[TBL] [Abstract] [Full Text] [Related]
11. Role of primary cilium in pancreatic ductal adenocarcinoma (Review).
Sabanovic B; Giulietti M; Piva F
Int J Oncol; 2020 Nov; 57(5):1095-1102. PubMed ID: 33491761
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic value of circulating tumor DNA in pancreatic cancer: a systematic review and meta-analysis.
Fang Z; Meng Q; Zhang B; Shi S; Liu J; Liang C; Hua J; Yu X; Xu J; Wang W
Aging (Albany NY); 2020 Dec; 13(2):2031-2048. PubMed ID: 33318293
[TBL] [Abstract] [Full Text] [Related]
13. CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma.
Cannon A; Thompson CM; Maurer HC; Atri P; Bhatia R; West S; Ghersi D; Olive KP; Kumar S; Batra SK
Clin Cancer Res; 2020 Nov; 26(22):6051-6063. PubMed ID: 32873571
[TBL] [Abstract] [Full Text] [Related]
14. The Integrated Analyses of Driver Genes Identify Key Biomarkers in Thyroid cancer.
Xu Q; Song A; Xie Q
Technol Cancer Res Treat; 2020; 19():1533033820940440. PubMed ID: 32812852
[TBL] [Abstract] [Full Text] [Related]
15. Foundation One Genomic Interrogation of Thyroid cancers in Patients With Metastatic Disease Requiring Systemic Therapy.
Iñiguez-Ariza NM; Jasim S; Ryder MM; Chintakuntlawar AV; Morris JC; Hilger CR; Menefee ME; Smallridge RC; Karlin NJ; Alcaino C; Bible KC
J Clin Endocrinol Metab; 2020 Jul; 105(7):e2346-57. PubMed ID: 32421817
[TBL] [Abstract] [Full Text] [Related]
16. Cold Shock Domain Containing E1 (CSDE1) Protein is Overexpressed and Can be Targeted to Inhibit Invasiveness in Pancreatic cancer Cells.
Liu H; Li X; Dun MD; Faulkner S; Jiang CC; Hondermarck H
Proteomics; 2020 May; 20(10):e1900331. PubMed ID: 32170829
[TBL] [Abstract] [Full Text] [Related]
17. Whole-Exome Sequencing of Matched Primary and Metastatic Papillary Thyroid cancer.
Masoodi T; Siraj AK; Siraj S; Azam S; Qadri Z; Albalawy WN; Parvathareddy SK; Al-Sobhi SS; Al-Dayel F; Alkuraya FS; Al-Kuraya KS
Thyroid; 2020 Jan; 30(1):42-56. PubMed ID: 31668133
[No Abstract] [Full Text] [Related]
18. Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid cancer: Subanalysis of the Sorafenib Phase III DECISION Trial.
Brose MS; Schlumbeger M; Jeffers M; Kappeler C; Meinhardt G; Peña CEA
Clin Cancer Res; 2019 Dec; 25(24):7370-7380. PubMed ID: 31558473
[TBL] [Abstract] [Full Text] [Related]
19. Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate Thyroid Nodules.
Goldner WS; Angell TE; McAdoo SL; Babiarz J; Sadow PM; Nabhan FA; Nasr C; Kloos RT
Thyroid; 2019 Nov; 29(11):1594-1605. PubMed ID: 31469053
[No Abstract] [Full Text] [Related]
20. Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC.
Alhothali M; Mathew M; Iyer G; Lawrence HR; Yang S; Chellappan S; Padmanabhan J
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31100813
[TBL] [Abstract] [Full Text] [Related]
[Next]
